About SPRINT-MS

Multiple Sclerosis (MS) is a chronic, inflammatory demyelinating disease of the central nervous system that affects 400,000 people in the US and 2 million people worldwide. Those affected with the disease are characterized by their progression into one of three variants: relapsing-remitting, secondary-progressive and primary-progressive. Despite recent improvements in pharmacotherapy for relapsing-remitting Multiple Sclerosis (RRMS), there are no therapies with demonstrated efficacy in progressive Multiple Sclerosis in the absence of relapses.

NN102 is a study to determine the safety, tolerability and activity of ibudilast (MN-166) administered twice daily over a 96 week period in subjects with primary and secondary-progressive multiple sclerosis. A total of 255 subjects were randomly assigned to two treatment arms (ibudilast or matching-placebo), and the study utilized advanced brain imaging to assess activity and correlate clinical activity with these imaging measures.